{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:57:45Z","timestamp":1790456265058,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M760146"],"award-info":[{"award-number":["2024M760146"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Epileptologica"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Epilepsy is a chronic neurological disorder marked by a persistent tendency to generate seizures, leading to substantial cognitive, behavioral, and psychosocial consequences. This study investigated psychiatric disorder-related adverse events (AEs) associated with antiseizure medications (ASMs) in children using the Food and\u00a0Drug\u00a0Administration Adverse Event Reporting System (FAERS) database.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study conducted a comprehensive analysis of FAERS data from 2004 to 2024, focusing on psychiatric AEs in children with epilepsy or seizures treated with ASMs. Signal values were computed using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 2539 preferred terms (PTs) were included, involving 25 system organ classifications (SOCs). Nervous system, skin and subcutaneous tissue, and psychiatric disorders are the three most common SOCs for ASMs in children. There were 24 ASMs, whose AEs involved psychiatric disorders, totaling 110 PTs and 214 drug-PT relationships. Psychotic symptoms (notably lorazepam and topiramate, <jats:italic>n<\/jats:italic>\u2009=\u2009116 and 109), substance dependence and abuse (notably pregabalin and clonazepam, <jats:italic>n<\/jats:italic>\u2009=\u2009291 and 110), and the other neuropsychiatric symptoms (notably levetiracetam and valproic acid, <jats:italic>n<\/jats:italic>\u2009=\u200970 and 62) were the common types of psychiatric disorder-related AEs of ASMs in children. A total of nine ASMs (brivaracetam, clonazepam, diazepam, eslicarbazepine, gabapentin, lamotrigine, lorazepam, perampanel, and tiagabine) were associated with suicidal and self-injurious behavior in children.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study highlights psychiatric AEs of ASMs in children, offering critical insights to improve clinical medication practices and enhance treatment safety. Further research with broader clinical data is needed to promote safe and rational medication use.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s42494-025-00223-5","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T02:02:44Z","timestamp":1747965764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Psychiatric disorders with antiseizure medications in children: an analysis of the FDA adverse event reporting system database"],"prefix":"10.1186","volume":"7","author":[{"given":"Jianxiong","family":"Gui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingman","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linxue","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiannan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"issue":"4","key":"223_CR1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/epi.12550","volume":"55","author":"RS Fisher","year":"2014","unstructured":"Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475\u201382.","journal-title":"Epilepsia"},{"issue":"10172","key":"223_CR2","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","volume":"393","author":"RD Thijs","year":"2019","unstructured":"Thijs RD, Surges R, O\u2019Brien TJ, Sander JW. Epilepsy in adults. Lancet. 2019;393(10172):689\u2013701.","journal-title":"Lancet"},{"issue":"2","key":"223_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/epi4.12010","volume":"2","author":"S Saxena","year":"2017","unstructured":"Saxena S, Li S. Defeating epilepsy: A global public health commitment. Epilepsia Open. 2017;2(2):153\u20135.","journal-title":"Epilepsia Open"},{"key":"223_CR4","doi-asserted-by":"publisher","first-page":"106949","DOI":"10.1016\/j.yebeh.2020.106949","volume":"105","author":"G Singh","year":"2020","unstructured":"Singh G, Sander JW. The global burden of epilepsy report: Implications for low- and middle-income countries. Epilepsy Behav. 2020;105:106949.","journal-title":"Epilepsy Behav"},{"issue":"9","key":"223_CR5","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/brain\/awab162","volume":"144","author":"JD Symonds","year":"2021","unstructured":"Symonds JD, Elliott KS, Shetty J, Armstrong M, Brunklaus A, Cutcutache I, et al. Early childhood epilepsies: epidemiology, classification, aetiology, and socio-economic determinants. Brain. 2021;144(9):2879\u201391.","journal-title":"Brain"},{"issue":"3","key":"223_CR6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1528-1157.1993.tb02586.x","volume":"34","author":"WA Hauser","year":"1993","unstructured":"Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935\u20131984. Epilepsia. 1993;34(3):453\u201368.","journal-title":"Epilepsia"},{"issue":"12","key":"223_CR7","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1111\/dmcn.15337","volume":"64","author":"S Auvin","year":"2022","unstructured":"Auvin S. Paediatric epilepsy and cognition. Dev Med Child Neurol. 2022;64(12):1444\u201352.","journal-title":"Dev Med Child Neurol"},{"issue":"13","key":"223_CR8","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1001\/jama.2022.3880","volume":"327","author":"AM Kanner","year":"2022","unstructured":"Kanner AM, Bicchi MM. Antiseizure Medications for Adults With Epilepsy: A Review. JAMA. 2022;327(13):1269\u201381.","journal-title":"JAMA"},{"key":"223_CR9","doi-asserted-by":"publisher","first-page":"111393","DOI":"10.1016\/j.fct.2020.111393","volume":"142","author":"J Patocka","year":"2020","unstructured":"Patocka J, Wu Q, Nepovimova E, Kuca K. Phenytoin - An anti-seizure drug: Overview of its chemistry, pharmacology and toxicology. Food Chem Toxicol. 2020;142:111393.","journal-title":"Food Chem Toxicol"},{"issue":"Suppl 3","key":"223_CR10","first-page":"S17","volume":"28","author":"WE Dodson","year":"1987","unstructured":"Dodson WE. Carbamazepine efficacy and utilization in children. Epilepsia. 1987;28(Suppl 3):S17-24.","journal-title":"Epilepsia"},{"issue":"15","key":"223_CR11","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","volume":"46","author":"RM Nanau","year":"2013","unstructured":"Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem. 2013;46(15):1323\u201338.","journal-title":"Clin Biochem"},{"key":"223_CR12","doi-asserted-by":"crossref","unstructured":"Culy CR, Goa KL. Lamotrigine. A review of its use in childhood epilepsy. Paediatr Drugs. 2000;2(4):299\u2013330.","DOI":"10.2165\/00128072-200002040-00006"},{"issue":"Suppl 5","key":"223_CR13","first-page":"S71","volume":"40","author":"TA Glauser","year":"1999","unstructured":"Glauser TA. Topiramate. Epilepsia. 1999;40(Suppl 5):S71-80.","journal-title":"Epilepsia"},{"issue":"2","key":"223_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/08830738050200020101","volume":"20","author":"F Vigevano","year":"2005","unstructured":"Vigevano F. Levetiracetam in pediatrics. J Child Neurol. 2005;20(2):87\u201393.","journal-title":"J Child Neurol"},{"issue":"6","key":"223_CR15","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/epi.13716","volume":"58","author":"A Strzelczyk","year":"2017","unstructured":"Strzelczyk A, Z\u00f6llner JP, Willems LM, Jost J, Paule E, Schubert-Bast S, et al. Lacosamide in status epilepticus: Systematic review of current evidence. Epilepsia. 2017;58(6):933\u201350.","journal-title":"Epilepsia"},{"issue":"s02","key":"223_CR16","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.33588\/rn.66S02.2018170","volume":"66","author":"JL Herranz","year":"2018","unstructured":"Herranz JL. Antiepileptic drugs. Rev Neurol. 2018;66(s02):S21\u20135.","journal-title":"Rev Neurol"},{"issue":"2","key":"223_CR17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/epi.17155","volume":"63","author":"V Pironi","year":"2022","unstructured":"Pironi V, Ciccone O, Beghi E, Paragua-Zuellig H, Patel AA, Giussani G, et al. Survey on the worldwide availability and affordability of antiseizure medications: Report of the ILAE Task Force on Access to Treatment. Epilepsia. 2022;63(2):335\u201351.","journal-title":"Epilepsia"},{"issue":"6","key":"223_CR18","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1517\/14740338.2011.588597","volume":"10","author":"SA Hamed","year":"2011","unstructured":"Hamed SA. Psychiatric symptomatologies and disorders related to epilepsy and antiepileptic medications. Expert Opin Drug Saf. 2011;10(6):913\u201334.","journal-title":"Expert Opin Drug Saf"},{"issue":"1\u20132","key":"223_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jns.2014.05.043","volume":"343","author":"A Verrotti","year":"2014","unstructured":"Verrotti A, Carrozzino D, Milioni M, Minna M, Fulcheri M. Epilepsy and its main psychiatric comorbidities in adults and children. J Neurol Sci. 2014;343(1\u20132):23\u20139.","journal-title":"J Neurol Sci"},{"issue":"8","key":"223_CR20","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1093\/brain\/awad038","volume":"146","author":"N Karadag","year":"2023","unstructured":"Karadag N, Shadrin AA, O\u2019Connell KS, Hindley GFL, Rahman Z, Parker N, et al. Identification of novel genomic risk loci shared between common epilepsies and psychiatric disorders. Brain. 2023;146(8):3392\u2013403.","journal-title":"Brain"},{"key":"223_CR21","doi-asserted-by":"publisher","first-page":"106669","DOI":"10.1016\/j.yebeh.2019.106669","volume":"102","author":"C Campbell","year":"2020","unstructured":"Campbell C, Cavalleri GL, Delanty N. Exploring the genetic overlap between psychiatric illness and epilepsy: A review. Epilepsy Behav. 2020;102:106669.","journal-title":"Epilepsy Behav"},{"issue":"10","key":"223_CR22","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1007\/s00431-023-05146-2","volume":"182","author":"M Zhang","year":"2023","unstructured":"Zhang M, Li H, Huang L, Liu Y, Jiao XF, Zeng L, et al. Drug-associated kidney injury in children: a disproportionality analysis of the FDA Adverse Event Reporting System. Eur J Pediatr. 2023;182(10):4655\u201361.","journal-title":"Eur J Pediatr"},{"key":"223_CR23","doi-asserted-by":"publisher","first-page":"877932","DOI":"10.3389\/fphar.2022.877932","volume":"13","author":"V Battini","year":"2022","unstructured":"Battini V, Mari A, Gringeri M, Casini F, Bergamaschi F, Mosini G, et al. Antibiotic-induced neutropenia in pediatric patients: new insights from pharmacoepidemiological analyses and a systematic review. Front Pharmacol. 2022;13:877932.","journal-title":"Front Pharmacol"},{"issue":"12","key":"223_CR24","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1111\/epi.14591","volume":"59","author":"EP Borrelli","year":"2018","unstructured":"Borrelli EP, Lee EY, Descoteaux AM, Kogut SJ, Caffrey AR. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System. Epilepsia. 2018;59(12):2318\u201324.","journal-title":"Epilepsia"},{"key":"223_CR25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.seizure.2024.03.009","volume":"117","author":"Z He","year":"2024","unstructured":"He Z, Liu C, Lin L, Feng G, Wu G. Real-world safety of Levetiracetam: Mining and analysis of its adverse drug reactions based on FAERS database. Seizure. 2024;117:253\u201360.","journal-title":"Seizure"},{"issue":"8","key":"223_CR26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13(8):519\u201323.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"223_CR27","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"223_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315\u201321.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"223_CR29","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","volume":"25","author":"A Szarfman","year":"2002","unstructured":"Szarfman A, Machado SG, O\u2019Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database. Drug Saf. 2002;25(6):381\u201392.","journal-title":"Drug Saf"},{"key":"223_CR30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","volume":"346","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Zhou L, Shen Y, Zhou Q, Ji Y, Zhu H. Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database. J Affect Disord. 2024;346:223\u20139.","journal-title":"J Affect Disord"},{"issue":"2","key":"223_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/17512433.2024.2306223","volume":"17","author":"Y Du","year":"2024","unstructured":"Du Y, Zhu J, Guo Z, Wang Z, Wang Y, Hu M, et al. Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022. Expert Rev Clin Pharmacol. 2024;17(2):189\u2013201.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"10","key":"223_CR32","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s40263-022-00955-9","volume":"36","author":"A Strzelczyk","year":"2022","unstructured":"Strzelczyk A, Schubert-Bast S. Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic Encephalopathies. CNS Drugs. 2022;36(10):1079\u2013111.","journal-title":"CNS Drugs"},{"issue":"2","key":"223_CR33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/archdischild-2017-313421","volume":"104","author":"FM Gibbon","year":"2019","unstructured":"Gibbon FM, Maccormac E, Gringras P. Sleep and epilepsy: unfortunate bedfellows. Arch Dis Child. 2019;104(2):189\u201392.","journal-title":"Arch Dis Child"},{"issue":"9","key":"223_CR34","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1111\/epi.17696","volume":"64","author":"M Aboukaoud","year":"2023","unstructured":"Aboukaoud M, Wilf-Yarkoni A, Maor E. Investigation of cardiac arrhythmia events in patients treated with lamotrigine: FDA adverse event reporing system analysis. Epilepsia. 2023;64(9):2322\u20139.","journal-title":"Epilepsia"},{"key":"223_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.yebeh.2017.08.039","volume":"76","author":"B Chen","year":"2017","unstructured":"Chen B, Choi H, Hirsch LJ, Katz A, Legge A, Buchsbaum R, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2017;76:24\u201331.","journal-title":"Epilepsy Behav"},{"issue":"2","key":"223_CR36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.yebeh.2011.03.015","volume":"21","author":"H Kato","year":"2011","unstructured":"Kato H, Fukatsu N, Noguchi T, Oshima T, Tadokoro Y, Kanemoto K. Lamotrigine improves aggression in patients with temporal lobe epilepsy. Epilepsy Behav. 2011;21(2):173\u20136.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"223_CR37","doi-asserted-by":"publisher","first-page":"451.e1","DOI":"10.1016\/j.genhosppsych.2014.03.008","volume":"36","author":"S Saito","year":"2014","unstructured":"Saito S, Shioda K, Nisijima K. Anger with murderous impulse induced by lamotrigine. Gen Hosp Psychiatry. 2014;36(4):451.e1-2.","journal-title":"Gen Hosp Psychiatry"},{"key":"223_CR38","doi-asserted-by":"crossref","unstructured":"Canitano R, Bozzi Y. Autism Spectrum Disorder with Epilepsy: A Research Protocol for a Clinical and Genetic Study. Genes. 2023;15(1).","DOI":"10.3390\/genes15010061"},{"issue":"2","key":"223_CR39","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.yebeh.2007.10.004","volume":"12","author":"HP Bootsma","year":"2008","unstructured":"Bootsma HP, Vos AM, Hulsman J, Lambrechts D, Leenen L, Majoie M, et al. Lamotrigine in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav. 2008;12(2):262\u20138.","journal-title":"Epilepsy Behav"},{"issue":"2","key":"223_CR40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1006\/ebeh.2001.0168","volume":"2","author":"AP Aldenkamp","year":"2001","unstructured":"Aldenkamp AP, Baker G. A Systematic Review of the Effects of Lamotrigine on Cognitive Function and Quality of Life. Epilepsy Behav. 2001;2(2):85\u201391.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"223_CR41","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1017\/S0317167100000366","volume":"26","author":"JM Dooley","year":"1999","unstructured":"Dooley JM, Camfield PR, Smith E, Langevin P, Ronen G. Topiramate in intractable childhood onset epilepsy\u2013a cautionary note. Can J Neurol Sci. 1999;26(4):271\u20133.","journal-title":"Can J Neurol Sci"},{"issue":"1","key":"223_CR42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40263-015-0303-6","volume":"30","author":"O Schjerning","year":"2016","unstructured":"Schjerning O, Rosenzweig M, Potteg\u00e5rd A, Damkier P, Nielsen J. Abuse Potential of Pregabalin: A Systematic Review. CNS Drugs. 2016;30(1):9\u201325.","journal-title":"CNS Drugs"},{"key":"223_CR43","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.eplepsyres.2016.04.003","volume":"123","author":"MJ Brodie","year":"2016","unstructured":"Brodie MJ, Chung S, Wade A, Quelen C, Guiraud-Diawara A, Francois C, et al. Clobazam and clonazepam use in epilepsy: Results from a UK database incident user cohort study. Epilepsy Res. 2016;123:68\u201374.","journal-title":"Epilepsy Res"},{"key":"223_CR44","doi-asserted-by":"crossref","unstructured":"Livingston JH, Beaumont D, Arzimanoglou A, Aicardi J. Vigabatrin in the treatment of epilepsy in children. Br J Clin Pharmacol. 1989;27 Suppl 1(Suppl 1):109s-12s.","DOI":"10.1111\/j.1365-2125.1989.tb03470.x"},{"issue":"6","key":"223_CR45","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/ana.25623","volume":"86","author":"JW Dreier","year":"2019","unstructured":"Dreier JW, Pedersen CB, Gasse C, Christensen J. Antiepileptic Drugs and Suicide: Role of Prior Suicidal Behavior and Parental Psychiatric Disorder. Ann Neurol. 2019;86(6):951\u201361.","journal-title":"Ann Neurol"},{"issue":"9","key":"223_CR46","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1001\/jamaneurol.2021.2480","volume":"78","author":"P Klein","year":"2021","unstructured":"Klein P, Devinsky O, French J, Harden C, Krauss GL, McCarter R, et al. Suicidality Risk of Newer Antiseizure Medications: A Meta-analysis. JAMA Neurol. 2021;78(9):1118\u201327.","journal-title":"JAMA Neurol"},{"issue":"2","key":"223_CR47","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1684\/j.1950-6945.2004.tb00053.x","volume":"6","author":"E Spina","year":"2004","unstructured":"Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord. 2004;6(2):57\u201375.","journal-title":"Epileptic Disord"},{"issue":"6","key":"223_CR48","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1177\/15357597241250159","volume":"24","author":"JA Salpekar","year":"2024","unstructured":"Salpekar JA, Ertenu DD. Common ground: we can comprehensively treat pediatric epilepsy and psychiatric comorbidities. Epilepsy currents. 2024;24(6):381\u20136.","journal-title":"Epilepsy currents"},{"issue":"3","key":"223_CR49","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1124\/pr.120.019539","volume":"72","author":"W L\u00f6scher","year":"2020","unstructured":"L\u00f6scher W, Potschka H, Sisodiya SM, Vezzani A. Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol Rev. 2020;72(3):606\u201338.","journal-title":"Pharmacol Rev"},{"issue":"3","key":"223_CR50","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.yebeh.2012.09.018","volume":"26","author":"P Perucca","year":"2013","unstructured":"Perucca P, Mula M. Antiepileptic drug effects on mood and behavior: molecular targets. Epilepsy Behav. 2013;26(3):440\u20139.","journal-title":"Epilepsy Behav"},{"issue":"2","key":"223_CR51","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2174\/187152707780363294","volume":"6","author":"G Sanacora","year":"2007","unstructured":"Sanacora G, Saricicek A. GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. CNS Neurol Disord: Drug Targets. 2007;6(2):127\u201340.","journal-title":"CNS Neurol Disord: Drug Targets"},{"issue":"9","key":"223_CR52","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.jpsychires.2013.05.001","volume":"47","author":"EF Coccaro","year":"2013","unstructured":"Coccaro EF, Lee R, Vezina P. Cerebrospinal fluid glutamate concentration correlates with impulsive aggression in human subjects. J Psychiatr Res. 2013;47(9):1247\u201353.","journal-title":"J Psychiatr Res"},{"issue":"4","key":"223_CR53","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s11065-007-9043-9","volume":"17","author":"DW Loring","year":"2007","unstructured":"Loring DW, Marino S, Meador KJ. Neuropsychological and behavioral effects of antiepilepsy drugs. Neuropsychol Rev. 2007;17(4):413\u201325.","journal-title":"Neuropsychol Rev"},{"key":"223_CR54","doi-asserted-by":"publisher","first-page":"2064027","DOI":"10.1155\/2018\/2064027","volume":"2018","author":"CC Hansen","year":"2018","unstructured":"Hansen CC, Ljung H, Brodtkorb E, Reimers A. Mechanisms Underlying Aggressive Behavior Induced by Antiepileptic Drugs: Focus on Topiramate, Levetiracetam, and Perampanel. Behav Neurol. 2018;2018:2064027.","journal-title":"Behav Neurol"},{"issue":"4","key":"223_CR55","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1517\/14740338.2015.1010506","volume":"14","author":"M Mula","year":"2015","unstructured":"Mula M, Sander JW. Suicide and epilepsy: do antiepileptic drugs increase the risk? Expert Opin Drug Saf. 2015;14(4):553\u20138.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"223_CR56","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S1525-5050(02)00052-5","volume":"3","author":"ES Krishnamoorthy","year":"2002","unstructured":"Krishnamoorthy ES, Trimble MR, Sander JW, Kanner AM. Forced normalization at the interface between epilepsy and psychiatry. Epilepsy Behav. 2002;3(4):303\u20138.","journal-title":"Epilepsy Behav"},{"issue":"6","key":"223_CR57","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"223_CR58","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11523-020-00738-6","volume":"15","author":"E Raschi","year":"2020","unstructured":"Raschi E, Gatti M, Gelsomino F, Ardizzoni A, Poluzzi E, De Ponti F. Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. Target Oncol. 2020;15(4):449\u201366.","journal-title":"Target Oncol"},{"issue":"1","key":"223_CR59","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s11689-021-09371-4","volume":"13","author":"AB Arnett","year":"2021","unstructured":"Arnett AB, Wang T, Eichler EE, Bernier RA. Reflections on the genetics-first approach to advancements in molecular genetic and neurobiological research on neurodevelopmental disorders. J Neurodev Disord. 2021;13(1):24.","journal-title":"J Neurodev Disord"}],"container-title":["Acta Epileptologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42494-025-00223-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42494-025-00223-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42494-025-00223-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T14:03:09Z","timestamp":1748008989000},"score":1,"resource":{"primary":{"URL":"https:\/\/aepi.biomedcentral.com\/articles\/10.1186\/s42494-025-00223-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["223"],"URL":"https:\/\/doi.org\/10.1186\/s42494-025-00223-5","relation":{},"ISSN":["2096-9384","2524-4434"],"issn-type":[{"value":"2096-9384","type":"print"},{"value":"2524-4434","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"assertion":[{"value":"10 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}